Other names: Bruton Tyrosine Kinase Inhibitor, Bruton's Tyrosine Kinase Inhibitor
 Bruton Tyrosine Kinase (BTK) inhibitors inhibit the enzyme BTK, which is a crucial part of the B-cell receptor signaling pathway. Certain B-cell leukemias and lymphomas use B-cell receptor signaling for growth and survival.
  The rationale for using BTK inhibitors in cancer, therefore, is to block this signaling and trigger cell death (of cancer).